<DOC>
	<DOCNO>NCT00085020</DOCNO>
	<brief_summary>RATIONALE : GW572016 may stop growth tumor cell block enzymes necessary growth . Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Giving GW572016 trastuzumab may kill tumor cell . PURPOSE : This phase I trial study side effect best dose GW572016 give together trastuzumab treat patient metastatic breast cancer overexpresses HER2/neu .</brief_summary>
	<brief_title>GW572016 Trastuzumab Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine optimally tolerate regimen GW572016 administer trastuzumab ( Herceptin^® ) patient metastatic breast cancer overexpresses HER2/neu . - Determine safety tolerability regimen patient . Secondary - Determine pharmacokinetic parameter regimen patient . - Determine clinical response patient treat regimen . OUTLINE : This open-label , multicenter , dose-escalation study GW572016 . Patients receive oral GW572016 daily day 1-28 trastuzumab ( Herceptin^® ) IV 90 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos GW572016 optimally tolerate regimen ( OTR ) determine . The OTR define dose precede 2 6 patient experience dose-limiting toxicity . Once OTR determine , 10-18 additional patient enter treated OTR . Patients follow 28 day . PROJECTED ACCRUAL : A total 3-35 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer Metastatic disease Measurable evaluable disease HER2/neu overexpression ( 2+ 3+ ) confirm immunohistochemistry and/or HER2 gene amplification fluorescence situ hybridization Brain metastasis treat surgery and/or radiotherapy allow provide follow criterion meet : Neurologic status stable 2 week discontinue dexamethasone No concurrent anticonvulsant induce metabolism ( e.g. , phenytoin , carbamazepine , phenobarbital ) 18 Male female Karnofsky 70100 % Life expectancy , At least 12 week Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL AST ALT ≤ 3 time upper limit normal ( ULN ) ( 5 time ULN patient liver metastasis ) Bilirubin &lt; 1.5 mg/dL Creatinine clearance &gt; 30 mL/min Cardiovascular LVEF &gt; 50 % Negative pregnancy test Fertile patient must use effective contraception 4 week study participation Adequate venous access Able swallow retain oral medication Prior adjuvant/neoadjuvant chemotherapy allow More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin . More 4 week since prior radiotherapy More 4 week since prior major surgery Recovered prior therapy More 28 day since prior participation another investigational study More 28 day since prior investigational drug extensive tumor , pleural effusion , parenchymal mass ) result dyspnea rest uncontrolled brain metastasis leptomeningeal disease prior myocardial infarction preexist cardiac dysfunction ( e.g. , congestive heart failure ) clinically significant cardiac disease angina pectoris symptomatic intrinsic pulmonary disease ( e.g. , asthma chronic obstructive pulmonary disease ) result dyspnea rest pregnant nursing active infection know hypersensitivity Chinese Hamster Ovary cell proteins component product know immediate delay hypersensitivity reaction idiosyncrasy product similar chemical composition study drug know contraindication trastuzumab ( Herceptin^® ) malabsorption syndrome disease significantly affect gastrointestinal function psychiatric disorder would preclude study compliance serious illness condition concurrent biologic therapy prior cumulative dose doxorubicin &gt; 400 mg/m^2 ( include liposomal doxorubicin ) concurrent hormonal therapy* concurrent glucocorticoid concurrent radiotherapy prior major resection stomach small bowel could affect absorption GW572016 concurrent cytotoxic therapy concurrent anticancer therapy concurrent investigational drug 28 day study treatment concurrent administration follow medication substance : Antibiotics Clarithromycin Erythromycin Troleandomycin Ciprofloxacin Rifampin Norfloxacin Rifabutin HIV antiviral Delaviridine Indinavir Nelfinavir Ritonavir Saquinavir Efavirenz Nevirapine Amprenavir Lopinavir Anticonvulsants Phenytoin Carbamazepine Phenobarbital Antidepressants Fluoxetine Nefazodone Fluvoxamine Antifungals Itraconazole Ketoconazole Fluconazole Voriconazole Antacids ( within 1 hour study drug administration ) Cimetidine Amiodarone Diltiazem Pioglitazone Hypericum perforatum ( St. John 's wort ) Grapefruit grapefruit juice Rifabutin Diethyldithiocarbamate Gestodene Mifepristone Modafinil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>